Is OVX1 a Suitable Marker for Endometrial Cancer?

Beck, Eberhard; Wagner, M.; Anselmino, Lisa; Xu, Feng; Bast, Robert C.; Jaeger, Wolfram

doi:10.1006/gyno.1997.4620

Cited by 24 publications

(14 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous evidence was brought that the concentration of CA125 can be actually increased in up to 60% of EC patients, 22 but its value was found to be above the diagnostic cutoff in a rather limited number of patients with stage I cancer, typically lower than 10%. 23 In our study population, the values of CA125 were higher than the diagnostic threshold in 15.6% of patients with a diagnosis of stage I EC, and this finding is in absolute agreement with data previously published by Beck et al, 24 who also showed that CA125 was elevated greater than 35 U/mL in 15.2% of patients with a diagnosis of cancer at this stage. Interestingly, HE4 seemingly exhibits a much greater diagnostic sensitivity than CA125 for early diagnosis of EC.…”

Section: Discussionsupporting

confidence: 92%

Aberrant MicroRNA Expression in Patients With Endometrial Cancer

Montagnana¹,

Benati²,

Danese³

et al. 2017

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Aberrant MicroRNA Expression in Patients With Endometrial Cancer

Montagnana¹,

Benati²,

Danese³

et al. 2017

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

show abstract

“…Another study reports that only 10% of patients with stage I and II disease have elevated CA125 levels (22). In addition, Beck et al demonstrated that 15% of stage I uterine cancer patients, as well as 33% of stage II and 62% of stage III patients have elevated CA125 levels (CA125 >35 U/ml) (15). Our data was consistent with these other studies, which indicate that CA125 exhibited a low sensitivity, 20.8% at a specificity of 95%, for surgical stage I endometrial cancers and a sensitivity of 32.9% at a specificity of 95% for patients with stage II-IV disease.…”

Section: Discussionmentioning

confidence: 99%

“…There have been a number of studies evaluating individual serum tumor markers in endometrial cancer such as CEA, CA72.4, CA19.9, CA15.3, and M-CSF and were shown to be elevated in only 20% to 30% of patients (11)(12)(13)(14)(15). The most commonly used tumor marker as an aid in the clinical management of endometrial cancer is CA125.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus

Moore

Brown

Miller

et al. 2008

Gynecologic Oncology

Self Cite

194

143

View full text Add to dashboard Cite

Objective-Tumor markers with increased sensitivity and specificity for endometrial cancer are needed to help monitor response to therapy and to detect recurrent disease. Currently, the tumor maker CA125 is utilized in this role with limited value. The objectives of this study were to examine the levels of several novel tumor markers HE4, SMRP, CA72.4 and CA125 as potential markers in patients diagnosed with endometrioid adenocarcinoma of the uterus.Methods-Preoperative serum samples from surgically staged patients with endometrioid adenocarcinoma of the uterus were analyzed for levels of HE4, SMRP, CA72-4 and CA125. Control samples were obtained from healthy postmenopausal women. Logistic regression models and receiver operating characteristic (ROC) curves were constructed for each tumor marker and for all combinations, with cross-validation analyses to obtain average sensitivities at set specificities of 90%, 95%, and 98%.Results-Serum samples from 156 healthy subjects and 171 patients with endometrial cancer (122 stage I, 17 stage II, 26 stage III, and 6 stage IV) were analyzed. At a 95% specificity, the sensitivities for differentiating between healthy subjects and all stages of cancer were 45.5% for HE4 and 24.6% for CA125. For stage I disease, HE4 yielded a 17.1% improvement in sensitivity compared with CA125.

show abstract

“…It is reported that the tumor antigen CA 125 is elevated in the serum of some patients with endometrial cancer [5]; levels of CA 125 seem to be increased in the majority of patients with advanced disease but in only about 10-20% of patients with stage I disease [6]. Several authors have found that higher serum CA 125 levels correlate with stage or histopathologic factors, but only a few studies have evaluated the clinical utility of serum CA 125 measurements in predicting extrauterine disease [7,8].…”

Section: Introductionmentioning

confidence: 98%

Serum CA 125 levels and lymph node metastasis in patients with endometrial cancer

Takač

Gorišek

2006

Wien Klin Wochenschr

View full text Add to dashboard Cite

The aim of this study was to evaluate the correlation of preoperative serum CA 125 levels and lymph node metastasis in patients with endometrial cancer. Preoperative levels of serum CA 125 were determined in 64 patients with endometrial cancer treated with total abdominal hysterectomy with a lymph node dissection as initial therapy. Lymph node status, determined by histopathology, was correlated with both normal and elevated CA 125 levels, determined preoperatively. A serum CA 125 level of >30 IU/ml was considered elevated. There were five patients (7.8%) with pelvic or paraaortic lymph node metastases and 59 patients (92.2%) without nodal metastases. In all five patients with lymph node metastases, serum CA 125 was within normal limits. Preoperative serum CA 125 levels were above normal in eight lymph node-negative patients. In the remaining group of 51 node-negative patients, serum CA 125 levels were within normal limits. Among the five lymph node-positive patients, four had endometrioid and one had serous papillary cancer. One patient had histologic grade 2 tumor and four patients had histologic grade 3. Preoperative serum CA 125 levels do not offer any information for predicting lymph node metastasis in patients with endometrial cancer.

show abstract

Is OVX1 a Suitable Marker for Endometrial Cancer?

Cited by 24 publications

References 11 publications

Aberrant MicroRNA Expression in Patients With Endometrial Cancer

Aberrant MicroRNA Expression in Patients With Endometrial Cancer

Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus

Serum CA 125 levels and lymph node metastasis in patients with endometrial cancer

Contact Info

Product

Resources

About